Hong Kong, 4 November 2026 — The Tamchy Special Financial Investment Territory (Tamchy SFIT) proposed the NextFinance Initiative at Hong Kong FinTech…
Cosentyx® (secukinumab) doubled sustained remission rates and demonstrated steroid-sparing effects vs placebo in Phase III trial¹Approval marks 11th US indication for Cosentyx, building on its decade-long established efficacy and safety profile across immune-mediated diseases¹Cosentyx PMR indication already approved in EU; additional regulatory reviews ongoing, including in Japan Basel, November 17, 2026 – Novartis today announced that the US Food and Drug Administration (FDA) approved Cosentyx® (secukinumab) 150 mg for the treatment of adult patients with polymyalgia rheumatica (PMR) who have had an inadequate…
